Rho to Bring Clinical Trial Proficiency to Multiple Conferences in November

Rho to highlight many areas of expertise at conferences across the country

What:                 Rho, a full-service contract research organization (CRO), will showcase its clinical trial expertise at three upcoming conferences: TEDMED, North American Cystic Fibrosis Conference (NACFC), and Human Abuse Liability & Abuse-Deterrent Formulation (HAL).  

 

  • TEDMED: Committed to advancing health and health systems and dedicated to sharing “ideas worth spreading”, TEDMED convenes and curates extraordinary people and ideas from all disciplines both inside and outside of medicine in pursuit of unexpected connections that accelerate innovation in health and medicine. Brook White, executive director, corporate communications, will attend on behalf of Rho.
  • North American Cystic Fibrosis Conference:  This annual meeting brings together scientists, clinicians, and caregivers from around the world to discuss and share ideas on the latest advances in cystic fibrosis research, care, and drug development and to exchange ideas about ways to improve the health and quality of life for people living with the disease. Jamie Arnott, project director, Caitlin Hirschman, clinical team lead, Andrea Mospan, senior research scientist, and Meagan Vaughn, research scientist, will represent Rho at NACFC.  All have recent experience in planning and conducting cystic fibrosis studies and will share their successes with a community committed to finding a cure.
  • Human Abuse Liability and Abuse-Deterrent Formulations Summit: Widely known as the leading industry event for overcoming technical, clinical and marketplace challenges of reducing the abuse potential of prescription drugs, Rho will send Ben Vaughn, principal statistical scientist, to HAL 2017. Covering topics currently making national news, including the opioid crisis, Vaughn’s focus on the statistical analysis of pain studies will bring an analytical perspective to conversations that are affecting policy and life-saving research.

Rho focuses on helping pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, including clinical operations, project management, data management, data standards and biostatistics, with extensive experience in pain products.

Who:                   Rho experts at TEDMED:

  •         Brook White, executive director, corporate communications

Rho experts at NACFC:

  • Jamie Arnott, project director
  • Caitlin Hirschman, clinical team lead
  • Andrea Mospan, senior research scientist
  • Meagan Vaughn, research scientist

Rho experts at HAL:

  • Ben Vaughn, principal statistical scientist

 

Where                 TEDMED, November 1-3, 2017

& When:                            La Quinta Resort and Spa

                49499 Eisenhower Dr

                La Quinta, CA 92253

               

NACFC, November 2-4, 2017

Indiana Convention Center

                                                100 S Capitol Ave

Indianapolis, IN 46225

 

HAL, November 6-7, 2017 

                                                Hyatt Regency Bethesda

1 Bethesda Metro Center

Bethesda, MD 20814

 

DETAILS:              For media inquiries, please contact Bernadette Miller at Largemouth Communications,                                   (703) 297-5992, bernadette@largemouthpr.com.

ABOUT:                Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 33 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.

                               

Back to news